School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211122, Jiangsu, China.
Biochim Biophys Acta Mol Basis Dis. 2025 Jan;1871(1):167535. doi: 10.1016/j.bbadis.2024.167535. Epub 2024 Oct 5.
Preoperative chemotherapy (PC) is an important component of Colorectal cancer (CRC) treatment, but its effects on the biological functions of fibroblasts and epithelial cells in CRC are unclear.
This study utilized bulk, single-cell, and spatial transcriptomic sequencing data from 22 independent cohorts of CRC. Through bioinformatics analysis and in vitro experiments, the research investigated the impact of PC on fibroblast and epithelial cells in CRC. Subpopulations associated with PC and CRC prognosis were identified, and a predictive model was constructed using machine learning.
PC significantly attenuated the pathways related to tumor progression in fibroblasts and epithelial cells. NOTCH3 + Fibroblast (NOTCH3 + Fib), TNNT1 + Epithelial (TNNT1 + Epi), and HSPA1A + Epithelial (HSPA1A + Epi) subpopulations were identified in the adjacent spatial region and were associated with poor prognosis in CRC. PC effectively diminished the presence of these subpopulations, concurrently inhibiting pathway activity and intercellular crosstalk. A risk signature model, named the Preoperative Chemotherapy Risk Signature Model (PCRSM), was constructed using machine learning. PCRSM emerged as an independent prognostic indicator for CRC, impacting both overall survival (OS) and recurrence-free survival (RFS), surpassing the performance of 89 previously published CRC risk signatures. Additionally, patients with a high PCRSM risk score showed sensitivity to fluorouracil-based adjuvant chemotherapy (FOLFOX) but resistance to single chemotherapy drugs (such as Bevacizumab and Oxaliplatin). Furthermore, this study predicted that patients with high PCRSM were resistant to anti-PD1therapy.
In conclusion, this study identified three cell subpopulations (NOTCH3 + Fib, TNNT1 + Epi, and HSPA1A + Epi) associated with PC, which can be targeted to improve the prognosis of CRC patients. The PCRSM model shows promise in enhancing the survival and treatment of CRC patients.
术前化疗(PC)是结直肠癌(CRC)治疗的重要组成部分,但它对 CRC 中成纤维细胞和上皮细胞的生物学功能的影响尚不清楚。
本研究利用来自 22 个独立 CRC 队列的 bulk、单细胞和空间转录组测序数据。通过生物信息学分析和体外实验,研究了 PC 对 CRC 中成纤维细胞和上皮细胞的影响。确定了与 PC 和 CRC 预后相关的亚群,并使用机器学习构建了预测模型。
PC 显著减弱了成纤维细胞和上皮细胞中与肿瘤进展相关的途径。在相邻的空间区域中鉴定出 NOTCH3+成纤维细胞(NOTCH3+Fib)、TNNT1+上皮细胞(TNNT1+Epi)和 HSPA1A+上皮细胞(HSPA1A+Epi)亚群,并且与 CRC 的不良预后相关。PC 有效地减少了这些亚群的存在,同时抑制了途径活性和细胞间串扰。使用机器学习构建了一个名为术前化疗风险签名模型(PCRSM)的风险签名模型。PCRSM 成为 CRC 的独立预后指标,影响总生存期(OS)和无复发生存期(RFS),优于 89 个先前发表的 CRC 风险签名。此外,高 PCRSM 风险评分的患者对氟尿嘧啶为基础的辅助化疗(FOLFOX)敏感,但对单化疗药物(如贝伐单抗和奥沙利铂)耐药。此外,本研究预测高 PCRSM 的患者对抗 PD1 治疗耐药。
总之,本研究鉴定出与 PC 相关的三种细胞亚群(NOTCH3+Fib、TNNT1+Epi 和 HSPA1A+Epi),可作为靶点以改善 CRC 患者的预后。PCRSM 模型在提高 CRC 患者的生存率和治疗效果方面具有潜力。